Ironwood Pharmaceuticals | IRWD - Net Income


Ironwood Pharmaceuticals reported $3.19M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Almirall EUR 19.58M 7M Dec/2025
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amarin USD -1.22M 6.51M Dec/2025
Ardelyx USD -37.6M 37.2M Mar/2026
Astellas Pharma JPY 141.83B 98.31B Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Charles River Laboratories USD -1.48M 13.36M Jun/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Incyte USD 585.6M 282.27M Jun/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
MacroGenics USD -36.77M 22.62M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Pacira USD 4.65M 1.74M Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY 113.2B 137.52B Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024